AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 5:28 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 5:28 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
AMN Healthcare Services (AMN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 4.76% and 1.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stocks' Earnings Due on Feb 15: WST, ITGR & More
by Debanjana Dey
Medical Products companies' quarterly results are likely to reflect strength in customer demand. Let's see how ITGR, WST, AMN and PACB are placed ahead of their earnings releases.
What Analyst Projections for Key Metrics Reveal About AMN Healthcare (AMN) Q4 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of AMN Healthcare (AMN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.
GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.
Cencora (COR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.
Will AMN Healthcare (AMN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
AMN Healthcare (AMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Here's How Much You'd Have If You Invested $1000 in AMN Healthcare Services a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
by Zacks Equity Research
AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Implied Volatility Surging for AMN Healthcare (AMN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AMN Healthcare (AMN) stock based on the movements in the options market lately.
AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.
AMN Healthcare (AMN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for AMN Healthcare (AMN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Implied Volatility Surging for AMN Healthcare (AMN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AMN Healthcare (AMN) stock based on the movements in the options market lately.
New Strong Sell Stocks for September 6th
by Zacks Equity Research
AMN, ARR and CFBK have been added to the Zacks Rank #5 (Strong Sell) List on September 6, 2023.
New Strong Sell Stocks for August 30th
by Zacks Equity Research
AFCG, AMN and DNOW have been added to the Zacks Rank #5 (Strong Sell) List on August 30, 2023.
AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.